Semax
Human observationalCommunity-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.
Overview
A peptide developed in Russia and used there in some clinical settings; used elsewhere as a nootropic. Evidence outside its origin is limited.
Mechanism
Proposed to modulate BDNF and neurotrophic signalling; human mechanism not firmly established.
Evidence
Some regional clinical use; robust independent RCT evidence is limited.
Community-reported information
Community reports vary. Anecdotal and unvalidated; general information only.
General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.
Half-life
Short (intranasal use common).
Storage
Refrigerate solutions.
Commonly reported side effects
- Not well characterised
- Nasal irritation (intranasal)
Legal status by region
- USNot FDA-approved; not a lawful supplement ingredient.
Legal status changes over time; verify locally before relying on this.
Citations
- Semax researchPubMed